Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30® tablets

Antiviral Therapy

Volumn 15, Issue 3, 2010, Pages 343-350

  Poerksen, Goenke ^a   Pollock, Louisa ^b   Moons, Peter ^c   Chesshyre, Emily ^d   Burger, David ^e   Khoo, Saye ^f   Molyneux, Elizabeth ^c  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c UNIVERSITY OF MALAWI   (Malawi)

^d ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG COMBINATION; DRUG DOSAGE FORM; LAMIVUDINE; NEVIRAPINE; STAVUDINE; STAVUDINE, LAMIVUDINE, NEVIRAPINE DRUG COMBINATION; TABLET;

ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALAWI; MALE; NONHUMAN; PRIORITY JOURNAL; TABLET; TREATMENT RESPONSE; VIRUS LOAD; ADMINISTRATION AND DOSAGE; ADOLESCENT; BLOOD; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG DOSAGE FORM; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFANT; PHYSIOLOGY; PRESCHOOL CHILD; THERAPEUTIC USE; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DOSAGE FORMS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; LAMIVUDINE; MALAWI; MALE; NEVIRAPINE; STAVUDINE; TABLETS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77952912223     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1544     Document Type: Article

References (25)

1. Malawi Paediatric Antiretroviral Treatment Group. Antiretroviral therapy for children in the routine setting in Malawi. Trans R Soc Trop Med Hyg 2007; 101:511-516.
2. UNICEF/World Health Organization. UNICEF/WHO technical consultation: improving access to appropriate paediatric ARV formulations. (Updated 3-4 November 2004. Accessed 12 August 2008.) Available from http://www.who.int/3by5/ en/finalreport.pdf
3. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access; recommendations for a public health approach. (Updated February 2006. Accessed 12 July 2008.) Available from http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf
4. Ministry of Health and Population. Treatment of AIDS: guidelines for the use of antiretroviral therapy in Malawi. 1st ed. Malawi: National AIDS commission 2003.
5. Corbett A, Hosseinipour M, Nyirenda J, et al. Pharmacokinetics between trade and generic liquid and split tablet formulations of lamivudine, stavudine and nevirapine in HIV infected Malawian children. Interscience Conference on Antimicrobial Agents and Chemotherapy. 16-19 December 2005, Washington, DC, USA. Poster 1106.
6. Lodha R, Upadhyay A, Kabra SK. Antiretroviral therapy in HIV-1 infected children. Indian Pediatr 2005; 42:789-796. (Pubitemid 41207495)
7. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis 2005; 41:100-107. (Pubitemid 40863751)
8. Ellis JC, L'Homme RF, Ewings FM, et al. Nevirapine concentrations in HIV-infected children treated with divided fixed dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther 2007; 12:253-260.
9. Pollock L, Else L, Poerksen G, et al. Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets Pollock. J Antimicrob Chemother 2009; 64:1251-1259.
10. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. (Updated 07 August 2006. Accessed 17 June 2008.) Available from http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf
11. Kikaire B, Khoo S, Walker AS, et al. Nevirapine clearance from plasma in African adults stopping therapy - a pharmacokinetic substudy. AIDS 2007; 21:733-737. (Pubitemid 46568630)
12. La Porte CJL, Back DJ, Blaschke T, et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Reviews in Antiviral Therapy 2006; 3:5-14.
13. Verweij-van Wissen CPWGM, Aarnoutse RE, Burger DM. Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 816:121-129.
14. World Health Organization/UNAIDS. HIV/AIDS epidemiological fact sheets. (Updated 2008. Accessed 9 September 2009.) Available from http://www.who.int/ countries/mwi/en
15. L'homme RF, Kabamba D, Ewings FM, et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 2008; 22:557-565.
16. Chokephaibulkit K, Plipat N, Cressey TR, et al. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS 2005; 19:1495-1499. (Pubitemid 41400695)
17. Roche. Drug pharmacokinetic profiles for lamivudine and stavudine. (Accessed 10 September 2008.) Available from http://www.hivpharmacology
18. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15:1-5.
19. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T>C polymorphism on NNRTI plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008; 61:914-918.
20. Ellis J, Molyneux EM. Experience of antir-retroviral treatment for HIV-infected children in Malawi: the 1st 12 months. Ann Trop Peadiatr 2007; 27:261-267. (Pubitemid 350167611)
21. Mulenga V, Fillekes Q, Kabamba D, et al. Pharmacokinetics of nevirapine in HIV-infected infants with body weight 3-6 kg taking paediatric fixed dose combination tablets. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 881.
22. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008; 8:477-489. (Pubitemid 352005822)
23. Violari A, Cotton M, Gibb D, et al. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants; Evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. 22-25 July 2007, Sydney, Australia. Abstract WESS103.
24. World Health Organization. WHO technical reference group meeting. Paediatric HIV/antiretroviral therapy and care guideline review. (Updated April 2008. Accessed 10 September 2008.) Available from http://www.who.int/hiv/pub/ paediatric/art-meeting-april2008/en/index.html
25. Ministry of Health and Population. Treatment of AIDS: guidelines for the use of antiretroviral therapy in Malawi. 3rd ed. Malawi: National AIDS commission 2008.